GSK3-targeted small molecules as therapies for Alzheimer’s disease
Authors
Krina Patel
Share
Annotation
Alzheimer’s disease (AD) is a progressive neurological disorder that affects memory, thinking, and behavior. It is one of the leading causes of dementia worldwide, and current treatments mainly focus on managing symptoms rather than slowing or stopping disease progression. Research has identified glycogen synthase kinase-3 (GSK3) as a key enzyme involved in abnormal tau phosphorylation, which contributes to the development of Alzheimer’s disease. Targeting GSK3 may provide a potential therapeutic approach. In this study, computational methods, including virtual screening and molecular docking, were used to evaluate small molecules as possible GSK3 inhibitors. Docking simulations were performed using SwissDock, and binding affinity was measured using FullFitness scores and estimated Gibbs free energy (ΔG). Several compounds demonstrated strong predicted binding within the enzyme’s active site, suggesting stable interactions. These results indicate that certain small molecules may have potential as GSK3-targeted therapies. However, further experimental testing would be required to confirm their effectiveness and safety.
Keywords
Authors
Krina Patel
Share
References:
“Alzheimer’s Disease: Get the Facts.” UsAgainstAlzheimer’s, 8 Nov. 2024, www.usagainstalzheimers.org/alzheimers-disease-get-facts?gad_source=1&gclid=Cj0KCQjwy46_BhDOARIsAIvmcwNeqQLbhsYM-QE56yv0OuhQzdpns24dbE7iiF7E5YHVmZAjt_arJrIaAmzrEALw_wcB. Accessed 23 Apr. 2025.
CDC. “About Alzheimer’s.” Alzheimer’s Disease and Dementia, 15 Aug. 2024, www.cdc.gov/alzheimers-dementia/about/alzheimers.html.
Skaria AP. The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care. 2022 Sep;28(10 Suppl):S188-S196. doi: 10.37765/ajmc.2022.89236. PMID: 36197132.
Li S, Li AJ, Zhao J, Santillo MF, Xia M. Acetylcholinesterase Inhibition Assays for High-Throughput Screening. Methods Mol Biol. 2022;2474:47-58. doi: 10.1007/978-1-0716-2213-1_6. PMID: 35294755; PMCID: PMC9440486.
Froede HC, Wilson IB, Kaufman H. Acetylcholinesterase: theory of noncompetitive inhibition. Arch Biochem Biophys. 1986 Jun;247(2):420-3. doi: 10.1016/0003-9861(86)90601-6. PMID: 3717952.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016 Jun 1;8(6):595-608. doi: 10.15252/emmm.201606210. PMID: 27025652; PMCID: PMC4888851.
Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci. 2015 Jun;18(6):800-6. doi: 10.1038/nn.4018. PMID: 26007213; PMCID: PMC4445458.
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016 Oct;139 Suppl 2(Suppl 2):136-153. doi: 10.1111/jnc.13607. Epub 2016 May 4. PMID: 26990767; PMCID: PMC5025335.
Beese, Megan. “Neuroinflammation: What Many Brain Diseases Have in Common - American Brain Foundation.” American Brain Foundation, 14 Jan. 2025, www.americanbrainfoundation.org/what-is-neuroinflammation/.
Kumar, Anil , et al. “Donepezil.” National Library of Medicine, StatPearls Publishing, 17 Aug. 2023, www.ncbi.nlm.nih.gov/books/NBK513257/.
Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008 Mar;104(6):1433-9. doi: 10.1111/j.1471-4159.2007.05194.x. Epub 2007 Dec 18. PMID: 18088381; PMCID: PMC3073119.
Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer's disease. Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118664. doi: 10.1016/j.bbamcr.2020.118664. Epub 2020 Jan 30. PMID: 32006534; PMCID: PMC7047718.
Other articles of the issue
